Abstract
Benzimidazole is a common kinase inhibitor scaffold and benzimidazole-based compounds interact with enzymes by multiple binding modes. In some cases, the benzimidazole acts as part of the hinge-binding motif, in others it has a scaffolding role without evidence for direct hinge binding. Several of these compounds are ATP-competitive inhibitors and show high selectivity by exploiting unique structural properties that distinguish one kinase from the majority of other kinases. However, the high specificity for a single target is not always sufficient. Thus another approach, called multi-target therapy, has been developed over the last few years. The simultaneous inhibition of various kinases may be useful because the disease is attacked at several relevant targets. Moreover, if a kinase becomes drug-resistant, a multitargeted drug can act on the other kinases. Some benzimidazole derivatives are multi-target inhibitors. In this article benzimidazole inhibitors are reported with their mechanisms of action, structure-activity relationship (SAR) and biological properties.
Keywords: ATP-competitive, benzimidazole, biological activity, kinase inhibition, multi-target inhibitor, SAR, selectivity.
Current Medicinal Chemistry
Title:Benzimidazole Derivatives as Kinase Inhibitors
Volume: 21 Issue: 20
Author(s): Laura Garuti, Marinella Roberti and Giovanni Bottegoni
Affiliation:
Keywords: ATP-competitive, benzimidazole, biological activity, kinase inhibition, multi-target inhibitor, SAR, selectivity.
Abstract: Benzimidazole is a common kinase inhibitor scaffold and benzimidazole-based compounds interact with enzymes by multiple binding modes. In some cases, the benzimidazole acts as part of the hinge-binding motif, in others it has a scaffolding role without evidence for direct hinge binding. Several of these compounds are ATP-competitive inhibitors and show high selectivity by exploiting unique structural properties that distinguish one kinase from the majority of other kinases. However, the high specificity for a single target is not always sufficient. Thus another approach, called multi-target therapy, has been developed over the last few years. The simultaneous inhibition of various kinases may be useful because the disease is attacked at several relevant targets. Moreover, if a kinase becomes drug-resistant, a multitargeted drug can act on the other kinases. Some benzimidazole derivatives are multi-target inhibitors. In this article benzimidazole inhibitors are reported with their mechanisms of action, structure-activity relationship (SAR) and biological properties.
Export Options
About this article
Cite this article as:
Garuti Laura, Roberti Marinella and Bottegoni Giovanni, Benzimidazole Derivatives as Kinase Inhibitors, Current Medicinal Chemistry 2014; 21 (20) . https://dx.doi.org/10.2174/0929867321666140217105714
DOI https://dx.doi.org/10.2174/0929867321666140217105714 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Genetic Variation at the Human MGMT Locus and its Biological Consequences
Current Pharmacogenomics The Blood-Brain Barrier in Multiple Sclerosis: microRNAs as Key Regulators
CNS & Neurological Disorders - Drug Targets Vitamin D and Vitamin D Analogs in Cancer Treatment
Current Drug Targets Vascular Endothelial Growth Factor (VEGF) Biochemistry and Development of Inhibitory Drugs
Current Drug Therapy Microenvironmental Interactions in Chronic Lymphocytic Leukemia: Hints for Pathogenesis and Identification of Targets for Rational Therapy
Current Pharmaceutical Design MiRNA-based Therapeutics for Lung Cancer
Current Pharmaceutical Design Alterations within the Osteo-Hematopoietic Niche in MDS and their Therapeutic Implications
Current Pharmaceutical Design Catechol-O-Methyltransferase (COMT)-Mediated Methylation Metabolism of Endogenous Bioactive Catechols and Modulation by Endobiotics and Xenobiotics: Importance in Pathophysiology and Pathogenesis
Current Drug Metabolism Synthesis of 5-Alkynyltetrandrine Derivatives and Evaluation of their Anticancer Activity on A549 Cell Lines
Anti-Cancer Agents in Medicinal Chemistry DNA Damage-inducing Compounds: Unraveling their Pleiotropic Effects Using High Throughput Sequencing
Current Medicinal Chemistry Therapeutic Cancer Vaccines: At Midway Between Immunology and Pharmacology
Current Cancer Drug Targets Reactive Oxygen Species, Cancer and Anti-Cancer Therapies
Current Chemical Biology Nitric Oxide, Peroxynitrite, Peroxynitrous Acid, Nitroxyl, Nitrogen Dioxide, Nitrous Oxide: Biochemical Mechanisms and Bioaction
Current Bioactive Compounds Transcriptional Analysis of JAK/STAT Signaling in Glioblastoma Multiforme
Current Pharmacogenomics and Personalized Medicine Radioiodinated Agents for Imaging Multidrug Resistant Tumors
Medicinal Chemistry Effects of Diet-Derived Molecules on the Tumor Microenvironment
Current Angiogenesis (Discontinued) COVID-19 and Autoimmune Diseases: A Systematic Review of Reported Cases
Current Rheumatology Reviews CD20-based Immunotherapy of B-cell Derived Hematologic Malignancies
Current Cancer Drug Targets Ascorbic Acid: An Old Player with a Broad Impact on Body Physiology Including Oxidative Stress Suppression and Immunomodulation: A Review
Mini-Reviews in Medicinal Chemistry A Review of Coumarin Derivatives in Pharmacotherapy of Breast Cancer
Current Medicinal Chemistry